Sao Paulo, August 23, 2013 -- Moody's América Latina ("Moody's") downgraded Brasil Pharma's ratings to Ba3 from Ba2 on the global scale and to A2.br from Aa3.br on the Brazilian national scale. The outlook for all ratings is stable.
Vollständigen Artikel bei Moodys lesen